Neuropace Stock Performance
| NPCE Stock | USD 12.29 0.44 3.71% |
On a scale of 0 to 100, Neuropace holds a performance score of 4. The company secures a Beta (Market Risk) of 1.65, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Please check Neuropace's value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neuropace's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.28) | Five Day Return (2.23) | Year To Date Return 2.33 | Ten Year Return (52.52) | All Time Return (52.52) |
1 | Insider Trading | 01/06/2025 |
2 | NeuroPace Inc Shares Up 4.71 percent on Jan 24 | 01/24/2025 |
3 | Disposition of 200 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3 | 01/30/2025 |
4 | Rapid Micro Biosystems, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/28/2025 |
5 | NeuroPace Inc Q4 2024 Earnings Report Preview What to Look For | 03/03/2025 |
6 | UPDATE -- NeuroPace to Present at the Leerink Partners Global Healthcare Conference | 03/04/2025 |
7 | NeuroPace Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ... | 03/05/2025 |
8 | NeuroPace Full Year 2024 Earnings EPS Beats Expectations | 03/06/2025 |
9 | NeuroPace, Inc. Annual Results Heres What Analysts Are Forecasting For This Year | 03/07/2025 |
10 | Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat | 03/11/2025 |
11 | Disposition of 179 shares by Rebecca Kuhn of Neuropace at 4.25 subject to Rule 16b-3 | 03/14/2025 |
12 | Acquisition by Rebecca Kuhn of 19850 shares of Neuropace at 10.04 subject to Rule 16b-3 | 03/20/2025 |
13 | Acquisition by Martha Morrell of 19850 shares of Neuropace at 12.3 subject to Rule 16b-3 | 03/24/2025 |
14 | NeuroPace Inc Stock Price Down 4.25 percent on Mar 27 | 03/27/2025 |
| Begin Period Cash Flow | 18.2 M |
Neuropace |
Neuropace Relative Risk vs. Return Landscape
If you would invest 1,119 in Neuropace on December 31, 2024 and sell it today you would earn a total of 110.00 from holding Neuropace or generate 9.83% return on investment over 90 days. Neuropace is currently generating 0.2252% in daily expected returns and assumes 3.8774% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Neuropace, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuropace Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuropace, and traders can use it to determine the average amount a Neuropace's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NPCE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.88 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Neuropace is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuropace by adding it to a well-diversified portfolio.
Neuropace Fundamentals Growth
Neuropace Stock prices reflect investors' perceptions of the future prospects and financial health of Neuropace, and Neuropace fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuropace Stock performance.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 406.42 M | ||||
| Shares Outstanding | 32.56 M | ||||
| Price To Book | 48.15 X | ||||
| Price To Sales | 4.83 X | ||||
| Revenue | 79.91 M | ||||
| Gross Profit | 59.09 M | ||||
| EBITDA | (16.57 M) | ||||
| Net Income | (27.14 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 73.34 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.27 X | ||||
| Cash Flow From Operations | (17.95 M) | ||||
| Earnings Per Share | (0.93) X | ||||
| Market Capitalization | 385.84 M | ||||
| Total Asset | 94.65 M | ||||
| Retained Earnings | (530.95 M) | ||||
| Working Capital | 66.18 M | ||||
About Neuropace Performance
By analyzing Neuropace's fundamental ratios, stakeholders can gain valuable insights into Neuropace's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neuropace has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neuropace has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 234.57 | 273.68 | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.27) | (0.29) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (3.39) | (3.22) |
Things to note about Neuropace performance evaluation
Checking the ongoing alerts about Neuropace for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuropace help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuropace had very high historical volatility over the last 90 days | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 59.09 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: NeuroPace Inc Stock Price Down 4.25 percent on Mar 27 |
- Analyzing Neuropace's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuropace's stock is overvalued or undervalued compared to its peers.
- Examining Neuropace's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuropace's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuropace's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuropace's stock. These opinions can provide insight into Neuropace's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |